Zhong, Wenge et al. published their patent in 2020 |CAS: 386704-04-7

The Article related to benzimidazole derivative preparation glp1r agonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application of 386704-04-7

On October 15, 2020, Zhong, Wenge; Guo, Wei published a patent.Application of 386704-04-7 The title of the patent was Benzimidazole derivatives as Glp-1R agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Provided herein are benzimidazole compounds of formula I and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alc. fatty liver disease, non-alc. steatohepatitis, and cardiovascular disease. Compounds of formula I wherein dashed double bond is either as single bond or a double bond; X1-X5 are independently N, CH; W is O, S, (un)substituted CH, NH and derivatives; ring B is 6-membered heteroaryl, 6-membered monocyclic ring, Ph; Y1 is N, NH, CH, CH2; ring C is cyclohexyl, Ph, pyridinyl; L is (un)substituted CH2, S, O, NH and derivatives; ring D is bicyclic heteroaryl; EE is COOH, -COCF3, -CH(OH)CF3, -CONH-CN, -CONH-OH, -CO-NH-OMe, etc.; T is -CH(RbRc); Ra, Rb and Rc are independently H, D, halo, CN, C1-6 alkyl, C1-6 alkoxy, etc.; R1 is H, D, halo, CN, OH, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is H, D, halo, CN, OH, oxo, C1-6 alkyl, etc.; R3 is H, D, CN, OH, oxo, C1-6 alkyl, C1-6 alkoxy, etc.; R4 is H, D, halo, OH, CN, C1-6 alkyl, C1-6 alkoxy, etc.; and their pharmaceutically acceptable salts, stereoisomers, solvates, hydrates as Glp-1R agonists in the treatment of diseases thereof, are claimed. Example compound II was prepared starting from 4-bromo-3-fluorobenzeneacetonitrile by using alcoholysis, heterocyclization, cross-coupling, and hydrolysis as the key steps. All the invention compounds were evaluated for their Glp-1R agonistic activity. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to benzimidazole derivative preparation glp1r agonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Akama, Tsutomu et al. published their patent in 2017 |CAS: 386704-04-7

The Article related to oxaborole ester preparation treatment parasite disease trypanosomosis, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Category: alcohols-buliding-blocks

On November 16, 2017, Akama, Tsutomu; Carter, David Scott; Halladay, Jason S.; Jacobs, Robert T.; Liu, Yang; Plattner, Jacob J.; Zhang, Yong-Kang; Witty, Michael John published a patent.Category: alcohols-buliding-blocks The title of the patent was Oxaborole esters and uses thereof. And the patent contained the following:

The present invention provides oxaborole ester compounds, e.g. I, and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Category: alcohols-buliding-blocks

The Article related to oxaborole ester preparation treatment parasite disease trypanosomosis, Organometallic and Organometalloidal Compounds: Boron Compounds and other aspects.Category: alcohols-buliding-blocks

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Shang, Rui et al. published their patent in 2022 |CAS: 386704-04-7

The Article related to thiophenol photocatalyst alkylsilane preparation defluorination alkylation, Organometallic and Organometalloidal Compounds: Silicon Compounds and other aspects.Related Products of 386704-04-7

On May 13, 2022, Shang, Rui; Liu, Can published a patent.Related Products of 386704-04-7 The title of the patent was Application method of thiophenol photocatalyst in defluorination alkylation or defluorination protonation reaction. And the patent contained the following:

The title method includes (1) mixing a trifluoromethyl compound (with a formula I as shown in Claim 2, such as trifluoromethyl (hetero)alkyl compounds, trifluoroacetamide compounds, etc.) and/or polyfluoroalkyl compound (with a formula II, such as pentafluoroacetamide compounds, etc.), thiophenol photocatalyst (4-methoxythiophenol, 4-methylthiophenol, etc.), formate salt (sodium formate, calcium formate, etc.) and organic solvent (DMF, THF, etc.) to form a reaction mixture. (2) Irradiating under the protection of inert gas for a defluorination reaction to obtain a difluoromethyl free radical and/or polyfluoroalkyl free radical intermediate product. (3) Reacting with unsaturated olefin (with formula III as shown in Claim 5, such as dimethyl(phenyl)(vinyl)silane, but-3-en-1-ol, etc.) to obtain a defluorination alkylation product (6-(3-(dimethyl(phenyl)silyl)-1,1-difluoropropyl)pyridin-2-amine, 5-(6-aminopyridin-2-yl)-5,5-difluoropentan-1-ol, etc.). (4) Or reacting the intermediate product as hydrogen donor with formate salt to obtain a defluorination protonation product. In formulas I-III, R is amido, ester group, aryl or heteroaryl; and R’ is or cycloalkyl. The thiophenol photocatalyst has the advantages of low cost and environment friendliness. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Related Products of 386704-04-7

The Article related to thiophenol photocatalyst alkylsilane preparation defluorination alkylation, Organometallic and Organometalloidal Compounds: Silicon Compounds and other aspects.Related Products of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Beaulieu, Pierre et al. published their patent in 2010 |CAS: 386704-04-7

The Article related to dibenzofuran preparation viral polymerase inhibitor treatment hepatitis c, Heterocyclic Compounds (One Hetero Atom): Areno- and Diarenofurans and other aspects.Product Details of 386704-04-7

On April 8, 2010, Beaulieu, Pierre; Bonneau, Pierre; Coulombe, Rene; Forgione, Pasquale; Gillard, James; Jakalian, Araz; Rancourt, Jean published a patent.Product Details of 386704-04-7 The title of the patent was Dibenzofuran derivatives as viral polymerase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of hepatitis C viral infection. And the patent contained the following:

The application provides compounds of formula I , useful as inhibitors of the hepatitis C virus NS5B polymerase. The application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other antiviral agent in the treatment of a hepatitis C viral infection in a mammal having or at risk of having the infection. Compounds of formula I wherein either X is absent and Y is O or Y is absent and X is O; n is 0 to 4; R2 is halo, Cn, NO2, SO3H, acyl, amino, etc.; R5 is H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, aryl, etc.; R6 is C3-7 cycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, aryl, etc.; and salts and esters thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their viral polymerase inhibitory activity. From the assay, it was determined that the tested compounds exhibited EC50 values below 40 μM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Product Details of 386704-04-7

The Article related to dibenzofuran preparation viral polymerase inhibitor treatment hepatitis c, Heterocyclic Compounds (One Hetero Atom): Areno- and Diarenofurans and other aspects.Product Details of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Quattropani, Anna et al. published their patent in 2020 |CAS: 386704-04-7

The Article related to piperazine preparation glycosidase inhibitor treatment tauopathy alzheimer, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Recommanded Product: (6-(Trifluoromethyl)pyridin-3-yl)methanol

On February 27, 2020, Quattropani, Anna; Kulkarni, Santosh S.; Rakesh, Paul; Giri, Awadut Gajendra published a patent.Recommanded Product: (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of spiro compounds as glycosidase inhibitors. And the patent contained the following:

The invention relates to compounds of formula I, and pharmaceutically usable derivatives, solvates, salts, prodrugs, tautomers, enantiomers, racemates and stereoisomers thereof, including mixtures thereof in all ratios and compounds of formula I, wherein one or more H atoms may be replaced by D (deuterium) which are useful as glycosidase inhibitors, useful in the treatment of tauopathies and Alzheimer’s disease. Compounds of formula I wherein, R is (un)branched alkyl; L is CH2, NH2 and derivatives, N(CH2)0-2, etc.; Q1 is CH2, CO; Q2 is CH2 and CO; n = 0 – 2; A is benzothiazolyl, benzofuranyl, imidazolpyridyl, etc.; Z is H, halo, CN, OH, etc.; are claimed. The example compound II was prepared by condensation of 3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione with 5-(1-chloroethyl)benzo[d]thiazole. Compounds I were evaluated for their glycosidase inhibtory activity (some data given). The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Recommanded Product: (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to piperazine preparation glycosidase inhibitor treatment tauopathy alzheimer, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Recommanded Product: (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Kuttruff, Christian Andreas et al. published their patent in 2021 |CAS: 386704-04-7

The Article related to pyridazinamine preparation autotaxin modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol

On January 28, 2021, Kuttruff, Christian Andreas; Godbout, Cedrickx; Koolman, Hannes Fiepko; Roth, Gerald Juergen published a patent.Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was N-Methyl-N-(6-(methoxy)pyridazin-3-yl)amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases and preparation thereof. And the patent contained the following:

The invention relates to N-methyl-N-(6-(methoxy)pyridazin-3-yl)amine derivatives of formula I as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemic sclerosis (SSc). Compounds of formula I wherein A is substituted pyridyl; E is (un)substituted Ph and (un)substituted pyridyl; K is substituted piperazinyl, substituted piperidinyl and substituted pyrrolidinyl; L and M are independently H, Me and CH2OH; LM can be taken together to form cyclopropyl; are claimed. 1-[4-(4-{1-[(6-{[6-(Trifluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-yl)amino]cyclopropyl}-phenyl)piperazin-l-yl]ethan-1-one (II) was prepared by N-arylation of 1-{4-[4-(1-aminocyclopropyl)phenyl]-piperazin-1-yl}ethan-1-one with 3-iodo-6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazine. The invention compounds were evaluated for their ATX modulatory activity. From the assay, it was determined that compound II exhibited IC50 value of 2.5 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to pyridazinamine preparation autotaxin modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Application In Synthesis of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Kuttruff, Christian Andreas et al. published their patent in 2021 |CAS: 386704-04-7

The Article related to pyridazinamine preparation autotaxin modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Computed Properties of 386704-04-7

On January 28, 2021, Kuttruff, Christian Andreas; Bretschneider, Tom; Godbout, Cedrickx; Koolman, Hannes Fiepko; Martyres, Domnic; Roth, Gerald Juergen published a patent.Computed Properties of 386704-04-7 The title of the patent was N-Methyl-N-(6-(methoxy)pyridazin-3-yl)amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases and preparation thereof. And the patent contained the following:

The invention relates to N-methyl-N-(6-(methoxy)pyridazin-3-yl)amine derivatives of formula I as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemic sclerosis (SSc). Compounds of formula I wherein A is substituted pyridyl; E is (un)substituted Ph and (un)substituted pyridyl; K is substituted piperazinyl, substituted piperidinyl, substituted 2,6-diazabicyclo[3.3]heptanyl, etc.; are claimed. 1-(6-(4-(((6-((6-(Trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)amino)methyl)phenyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (II) was prepared by N-arylation of 1-(6-(4-(aminomethyl)phenyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one with 3-Iodo-6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazine. The invention compounds were evaluated for their ATX modulatory activity. From the assay, it was determined that compound II exhibited IC50 value of 3.4 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Computed Properties of 386704-04-7

The Article related to pyridazinamine preparation autotaxin modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Computed Properties of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Guzzo, Peter et al. published their patent in 2009 |CAS: 386704-04-7

The Article related to pyridoindole derivative preparation mch antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol

On July 16, 2009, Guzzo, Peter; Surman, Matthew David; Henderson, Alan John; Jiang, May Xiaowu; Hadden, Mark; Grabowski, James published a patent.Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Pyridoindole derivatives as MCH antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

The invention relates to pyridoindole derivatives of formula I, which are MCH antagonists and useful in the treatment of various diseases. Compounds of formula I wherein R1 is H and (un)substituted alkyl; R2-R4 are independently H, alkoxy, alkylthio, alkyl, halo, CF3 and CN; G is (un)substituted -CH2NH- and derivatives and (un)substituted -NHCH2 and derivatives; R8-R11 are independently H and (un)substituted alkyl; R14 and R15 are independently H and halogen; L is -CH2O-, -CH2CH2-, -CH=CH- and a bond; B is (hetero)aryl and cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine; are claimed. Example compound II·HCl was prepared via cyclization of 3-bromophenylhydrazine with N-Boc-4-oxopiperidine; the resulting tert-Bu 7-bromo-3,4-dihydro-1H-pyrido[4,3-b]indole-2(5H)-carboxylate underwent N-methylation to give tert-Bu 7-bromo-5-methyl-3,4-dihydro-1H-pyrido[4,3-b]indole-2(5H)-carboxylate, which underwent condensation with 4-benzyloxypyridin-2(1H)-one to give tert-Bu 7-[4-benzyloxy-2-oxopyridin-1(2H)-yl]-5-methyl-3,4-dihydro-1H-pyrido[4,3-b]indole-2(5H)-carboxylate, which underwent hydrolysis to give II·HCl. All the invention compounds were evaluated for their MCH1 antagonistic activity. From the assay, it was determined that the tested compounds exhibited the Ki values of ≤ 3.5 μM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to pyridoindole derivative preparation mch antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Reference of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Kuttruff, Christian Andreas et al. published their patent in 2021 |CAS: 386704-04-7

The Article related to pyridazinylcyclopropanecarboxamide preparation autotaxin modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.HPLC of Formula: 386704-04-7

On January 28, 2021, Kuttruff, Christian Andreas; Bretschneider, Tom; Godbout, Cedrickx; Koolman, Hannes Fiepko; Martyres, Domnic; Roth, Gerald Juergen published a patent.HPLC of Formula: 386704-04-7 The title of the patent was 1-(6-(Methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases and preparation thereof. And the patent contained the following:

The invention relates to 1-(6-(methoxy)pyridazin-3-yl)cyclopropan-1-carboxamide derivatives of formula I as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemic sclerosis (SSc). Compounds of formula I wherein A is substituted pyridyl; E is (un)substituted Ph and (un)substituted pyridyl; K is substituted piperazinyl, substituted piperidinyl, substituted 2,6-diazabicyclo[3.3]heptanyl, etc.; are claimed. N-(4-(7-Acetyl-2,7-diazaspiro[3.5]nonan-2-yl)benzyl)-1-(6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide (II) was prepared by amidation of 1-(6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)cyclopropane-1-carboxylic acid with 1-(2-(4-(aminomethyl)phenyl)-2,7-diazaspiro[3.5]nonan-7-yl)ethan-1-one. The invention compounds were evaluated for their ATX modulatory activity. From the assay, it was determined that compound II exhibited IC50 value of 4.0 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).HPLC of Formula: 386704-04-7

The Article related to pyridazinylcyclopropanecarboxamide preparation autotaxin modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.HPLC of Formula: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Yu, Guixue et al. published their patent in 2010 |CAS: 386704-04-7

The Article related to azabicyclic heterocycle triazolopyridazine preparation cannabinoid receptor cb1 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Application of 386704-04-7

On October 19, 2010, Yu, Guixue; Ewing, William R.; Mikkilineni, Amarendra B.; Pendri, Annapurna; Ellsworth, Bruce A.; Sher, Philip M.; Gerritz, Samuel; Sun, Chongqing; Murugesan, Natesan; Wu, Ximao published a patent.Application of 386704-04-7 The title of the patent was Preparation of azabicyclic heterocycles as cannabinoid receptor modulators. And the patent contained the following:

The present application describes compounds I [R1, R2 = halo, CN, alkyl, etc.; R3 = H alkyl, alkenyl, cycloalkyl, etc.; R4 is absent when n is a double bond; R4 = H, alkyl, cycloalkyl, etc.; R5 = halo, (un)substituted OH, NH2, etc. when m is a single bond; R5 = O when m = a double bond; m, n = a single or double bond; when m is a single bond, n is a double bond; when m is a double bond, n is a single bond], pharmaceutical compositions comprising at least one compound I and optionally one or more addnl. therapeutic agents and methods of treatment using the compounds I both alone and in combination with one or more addnl. therapeutic agents. Over 40 compounds I were prepared E.g., a multi-step synthesis of II, starting from dichloromandelic anhydride and hydrazine dihydrochloride, was given. The exemplified compounds I showed the CB-1 receptor binding Ki values in the range of 0.01 nM to 10000 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to azabicyclic heterocycle triazolopyridazine preparation cannabinoid receptor cb1 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts